Curis, Inc. (CRIS)

Market Cap	89.71M
Revenue (ttm)	10.02M
Net Income (ttm)	-47.41M
Shares Out	5.89M
EPS (ttm)	-8.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,555
Open	16.50
Previous Close	15.95
Day's Range	14.63 - 16.50
52-Week Range	0.38 - 17.49
Beta	3.76
Analysts	Strong Buy
Price Target	37.33 (+145.27%)
Earnings Date	May 2, 2024

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 1, 2000
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: CRIS

Financial Performance

In 2023, Curis's revenue was $10.02 million, a decrease of -1.37% compared to the previous year's $10.16 million. Losses were -$47.41 million, -16.34% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price forecast is $37.33, which is an increase of 145.27% from the latest price.

Price Target

$37.33

(145.27% upside)

Analyst Consensus: Strong Buy